Bristlecone Advisors LLC Purchases New Position in Sana Biotechnology, Inc. (NASDAQ:SANA)

by · The Markets Daily

Bristlecone Advisors LLC purchased a new stake in Sana Biotechnology, Inc. (NASDAQ:SANA – Free Report) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 50,000 shares of the company’s stock, valued at approximately $208,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Vanguard Group Inc. lifted its position in Sana Biotechnology by 24.1% in the first quarter. Vanguard Group Inc. now owns 12,155,173 shares of the company’s stock valued at $121,552,000 after acquiring an additional 2,358,089 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its position in Sana Biotechnology by 2.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 3,695,459 shares of the company’s stock valued at $36,956,000 after acquiring an additional 101,434 shares during the last quarter. Capital World Investors lifted its position in Sana Biotechnology by 255.8% in the first quarter. Capital World Investors now owns 5,449,035 shares of the company’s stock valued at $54,490,000 after acquiring an additional 3,917,728 shares during the last quarter. Integral Health Asset Management LLC lifted its position in Sana Biotechnology by 22.4% in the second quarter. Integral Health Asset Management LLC now owns 1,200,000 shares of the company’s stock valued at $6,552,000 after acquiring an additional 220,000 shares during the last quarter. Finally, Baillie Gifford & Co. raised its holdings in shares of Sana Biotechnology by 5.0% in the first quarter. Baillie Gifford & Co. now owns 10,656,279 shares of the company’s stock valued at $106,563,000 after buying an additional 506,262 shares during the last quarter. 88.23% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the stock. HC Wainwright reduced their target price on shares of Sana Biotechnology from $12.00 to $11.00 and set a “buy” rating for the company in a report on Friday, August 9th. Citigroup upped their target price on shares of Sana Biotechnology from $8.00 to $15.00 and gave the company a “buy” rating in a report on Friday, August 9th.

View Our Latest Report on SANA

Insider Transactions at Sana Biotechnology

In other Sana Biotechnology news, Director Richard Mulligan sold 150,000 shares of the company’s stock in a transaction dated Tuesday, September 24th. The shares were sold at an average price of $4.08, for a total transaction of $612,000.00. Following the transaction, the director now directly owns 2,848,121 shares in the company, valued at approximately $11,620,333.68. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 31.10% of the company’s stock.

Sana Biotechnology Stock Performance

Shares of NASDAQ:SANA opened at $3.76 on Monday. The company has a 50-day simple moving average of $4.63 and a 200-day simple moving average of $6.11. Sana Biotechnology, Inc. has a one year low of $2.74 and a one year high of $12.00. The stock has a market capitalization of $832.85 million, a price-to-earnings ratio of -2.46 and a beta of 1.42.

Sana Biotechnology (NASDAQ:SANA – Get Free Report) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.04). As a group, research analysts forecast that Sana Biotechnology, Inc. will post -1.13 EPS for the current fiscal year.

Sana Biotechnology Company Profile

(Free Report)

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.

Read More